Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the first quarter ended March 31, 2015.

The Company had $97.6 million in cash, cash equivalents and marketable securities as of March 31, 2015, compared to $122.7 million at December 31, 2014. Operating expenses of $27.1 million for the quarter ended March 31, 2015 increased by $2.4 million compared to the quarter ended December 31, 2014 primarily as a result of higher headcount and increased manufacturing expenses.

The net loss allocable to common stockholders for the quarter ended March 31, 2015 was $26.2 million, or $0.97 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended December 31, 2014 was $22.3 million, or $0.85 per basic and diluted share. (Original Source)

Shares of Dynavax closed yesterday at $19.57 . DVAX has a 1-year high of $26.89 and a 1-year low of $12.50. The stock’s 50-day moving average is $22.57 and its 200-day moving average is $18.35.

On the ratings front, Dynavax has been the subject of a number of recent research reports. In a report issued on March 23, J.P. Morgan analyst Anupam Rama upgraded DVAX to Buy, with a price target of $36, which represents a potential upside of 84.0% from where the stock is currently trading. Separately, on March 2, MLV & Co.’s Vernon Bernardino reiterated a Buy rating on the stock and has a price target of $25.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Anupam Rama and Vernon Bernardino have a total average return of 56.0% and -13.7% respectively. Rama has a success rate of 66.7% and is ranked #672 out of 3594 analysts, while Bernardino has a success rate of 23.2% and is ranked #3559.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The Company is engaged in thedevelopment for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.